ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Sino Biopharmaceutical Ltd. ?
1
High Management Efficiency with a high ROE of 94.58%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 32.34
3
Poor long term growth as Operating profit has grown by an annual rate 3.69% of over the last 5 years
4
Positive results in Jun 25
- ROCE(HY) Highest at 11.67%
- INTEREST COVERAGE RATIO(Q) Highest at 3,529.94
- RAW MATERIAL COST(Y) Fallen by -0.83% (YoY)
5
With ROE of 39.17%, it has a Very Attractive valuation with a 4.48 Price to Book Value
- Over the past year, while the stock has generated a return of 60.25%, its profits have risen by 153.7% ; the PEG ratio of the company is 0.1
6
Market Beating performance in long term as well as near term
- Along with generating 60.25% returns in the last 1 year, the stock has outperformed Hang Seng Hong Kong in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Sino Biopharmaceutical Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sino Biopharmaceutical Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Sino Biopharmaceutical Ltd.
60.25%
7.34
45.42%
Hang Seng Hong Kong
8.25%
0.41
19.93%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.51%
EBIT Growth (5y)
3.69%
EBIT to Interest (avg)
32.34
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.63
Tax Ratio
25.58%
Dividend Payout Ratio
65.98%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
134.35%
ROE (avg)
94.58%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
4.48
EV to EBIT
28.74
EV to EBITDA
22.18
EV to Capital Employed
5.11
EV to Sales
4.94
PEG Ratio
0.07
Dividend Yield
98.70%
ROCE (Latest)
17.78%
ROE (Latest)
39.17%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
ROCE(HY)
Highest at 11.67%
INTEREST COVERAGE RATIO(Q)
Highest at 3,529.94
RAW MATERIAL COST(Y)
Fallen by -0.83% (YoY
CASH AND EQV(HY)
Highest at HKD 21,716.97 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -23.57 %
NET SALES(Q)
Highest at HKD 18,877.96 MM
OPERATING PROFIT(Q)
Highest at HKD 4,671.51 MM
PRE-TAX PROFIT(Q)
Highest at HKD 5,839.62 MM
NET PROFIT(Q)
Highest at HKD 3,159.37 MM
EPS(Q)
Highest at HKD 0.2
-1What is not working for the Company
OPERATING PROFIT MARGIN(Q)
Lowest at 24.75 %
Here's what is working for Sino Biopharmaceutical Ltd.
Interest Coverage Ratio
Highest at 3,529.94
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales
Highest at HKD 18,877.96 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (HKD MM)
Operating Profit
Highest at HKD 4,671.51 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (HKD MM)
Pre-Tax Profit
Highest at HKD 5,839.62 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (HKD MM)
Net Profit
Highest at HKD 3,159.37 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
Net Profit
At HKD 3,159.37 MM has Grown at 102%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
EPS
Highest at HKD 0.2
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (HKD)
Cash and Eqv
Highest at HKD 21,716.97 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -23.57 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -0.83% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Sino Biopharmaceutical Ltd.
Operating Profit Margin
Lowest at 24.75 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Non Operating Income
Highest at HKD 0.3 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
